细胞色素P450 3A 选择性探针药物的评价

摘要/Abstract

摘要： 理想的细胞色素P450 3A(CYP3A) 探针药物有助于检测CYP3A 活性, 辅助临床合理用药。本文对CYP3A 选择性探针药物进行比较和综合分析, 评价各种CYP3A 选择性探针药物的特点, 阐明对临床合理用药的指导意义。在已筛选的CYP3A 选择性探针药物中, 咪哒唑仑是一较理想的探药。

关键词: 细胞色素P450 3A, 探药, 选择性, 评价

Abstract: Ideal probes for CYP3A can provide instruction for rationally clinical drug use.Comprehensive comparison and analysis were used for the present probes to evaluate the applicative characteristics of different selective probes for CYP3A and to indicate clinical value in rational drug therapy.Among the series of CYP3A probes, midazolam is considered the best one.

Key words: CYP3A, probes, selectivity, evaluation

中图分类号:

R966

朱学慧, 娄建石. 细胞色素P450 3A 选择性探针药物的评价[J]. 中国临床药理学与治疗学, 2004, 9(4): 365-369.

ZHU Xue-Hui, LOU Jian-Shi. Evaluation on selective probes for CYP3A[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 365-369.

参考文献

1 Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Do-brinska MR, et al.In-vivo phenotyping for CYP3A by a singlepoint determination of midazolam plasma concentration [J]. Pharmacogenetics, 2001;11(9):781-91
2 Lee JI, Chaves G, Amico JA, Kroboth PD, Wilson JW, Frye RF.Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping[J]. Pharmacogene Genom, 2002;72(6):718-28
3 Gorski JC, Stephen DH, David RJ, Mark VB, Steven AW. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A(CYP3A) subfamily[J].Biochem Pharmacol, 1994;47(9):1643-53
4 Watkins PB.Noninvasive tests of CYP3A enzymes[J].Pharmacogenetics, 1994;4(4):171-84
5 Lane EA, Parashos I.Drug pharmacokinetics and the carbon dioxide breath test[J].Drug pharmacokinet Biopharm, 1986; 14(1):29-49
6 Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, et al.P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients[J].Clin Pharmacol Ther, 1994;56(3):253-60
7 Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK.Urinary excretion of 6[beta]-hydroxycortisol as an in-vivo marker for CYP3A induction:applications and recommendations [J].Clin Pharmacol Ther, 1998;63(6):617-22
8 Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, et al.Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol[J].Clin Pharmacol Ther, 1992;51(1):18-23
9 Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al.Absence of correlation among three putative in-vivo probes of human cytochrome P-4503A4 activity in young healthy men [J].Clin Pharmacol Ther, 1993; 54(6):621-9
10 Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al.Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450 ⅢA (CYP3A) activity[J].Clin Pharmacol Ther, 1992;52(3):265-73
11 Gotzkowsky SK, Kashuba ADM, Hall W, Kulawy RW, Beck DJ, Rocci ML Jr, et al.Poor correlation between 24-hour urinary 6[beta]-hydroxycortisol:cortisol molar ratios(CMR) and plasma midazolam clearance (MDZ CL) as measures of hepatic CYP3A activity[J].Clin Pharmacol Ther, 1999;65(5):167
12 Ndanusa BU, Mustapha A, Abdu-Aguye I.The effect of single doses of rifampicin on the pharmacokinetics of oral nifedipine [J].J Pharm Biomed Anal, 1997;15(9-10):1571-5
13 Kleinbloesem CH, Brummelen P van, Faber H, Danhof M, Vermeulen NPE, Breimer DD, et al.Variability in nifedipine pharmacokinetics:a new oxidation polymorphism in man[J]. Biochem Pharmacol, 1984;33(22):3721-4
14 Schellens JH, Ghabrial H, van der Wart HH, Bakker EN, Wilkinson GR, Breimer DD, et al.Differential effects of qunidine on the disposition of nifedipine, sparteine and mephenytoin in humans[J].Clin Pharmacol Ther, 1991;50(5 pt 1):520-8
15 Cakaloglu Y, Tredger JM, Devlin J, Williams R.Importance of cytochrome P-450 Ⅲ A activity in determining dosage and blood levels of FK 506 and cy closporine in liver transplant recipients[J].Hepatology, 1994;20(2):309-16
16 Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T. The lignocaine metabolite(MEGX) liver function test and P-450 induction in human[J].Br J Clin Pharmacol, 1998;46(6): 535-9
17 Guitton J, Buronfosse T, Desage M, Lepape A, Brazier JL, Beaune P.Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil [J].Biochem Pharmacol, 1997;53(11):1613-9
18 Krivoruk Y, KinironsMT, Wood AJJ, WoodM.Alfentanil disposition in-vivo is mediated by CYP3A4 in human[J].Anesthesiology, 1994;81(6):A380
19 Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K.Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe[J].Anesthesiology, 1997;87(1):26-35
20 Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E.Midazolam is metabolized by at least three different cytochrome P450 enzymes [J].Br J Anaesth, 1994;73(5): 658-61
21 Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al.Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel.Lack of prediction by the erythromycin breath test[J].Drug Metab Dispos, 1994;22 (6):947-55
22 Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al.Use of midazolam as a human cytochrome P450 3A probe:Ⅰ.In vitro-in vivo correlations in liver transplant patients[J].J Pharmacol Exp Ther, 1994;271(1):549-56
23 Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al.The erythromycin breath test predicts the clearance of midazolam[J].Clin Pharmacol Ther, 1995;57 (1):16-24
24 Thummel KE, Shen DD, Bacchi CE, McVicar JP, Marsh CL, Perkins JD, et al.Induction of human hepatic P4503A3/4 by phenytoin[J].Hepatology, 1992;16(6):160A
25 Olkkola KT, Aranko K, Luurila H, Hiller A, Sarnivaara L, Himberg JJ, et al.A potentially hazardous interaction between erythromycin and midazolam[J].Clin Pharmacol Ther, 1993; 53(3):298-305
26 Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C.Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects[J].J Clin Pharmacol, 1989;29(3):272-7
27 Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al.Use of midazolam as a human cytochrome P450 3A probe:Ⅱ.Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation[J].J Pharmacol Exp Ther, 1994;271(1):557-66
28 Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH.Single plasma sampling to predict oral clearance of CYP3A probe mid-azolam[J].Acta Pharmacol Sin, 2001;22(7):634-8
29 王军升, 许振华, 周宏灏.细胞色素P4503A4 与药物氧化代谢[J].中国临床药理学杂志, 1996;12(4):231-5
30 Torben LN, Birgitte BR, Jean-Pierre F, Philippe B, Kim B. In vitro metabolism of quinidine:The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes[J].J Pharmacol Exp Ther, 1999;289(1):31-7
31 Jennifer AL, Gregory LK, Susan MAR, Anne NN, Irim SK, Angela DMK, et al.Cisapride:A potential model substrate to assess cytochrome P4503A4 activity in vivo[J].Clin Pharmacol Ther, 2003;73(3):209-22
32 Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al.Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein[J].Pharmaceu Resea, 1999;16(3):408-14

[1]	徐俪颖王淑华张高松黄继汉黄小民. 和胃止泻胶囊治疗腹泻患者的临床疗效和模型化评价[J]. 中国临床药理学与治疗学, 2022, 27(1): 47-55.
[2]	王媛媛, 洪钰, 张磊, 殷方雄, 雷婷, 朱熙. 儿科人血白蛋白药物利用评价标准的建立与应用[J]. 中国临床药理学与治疗学, 2021, 26(6): 653-661.
[3]	郑斌婕, 刘娜, 曾祥昌, 黄馨仪, 陈露露, 欧阳冬生. 肠道菌群对药物代谢动力学的影响及其在仿制药质量与疗效一致性评价中的思考[J]. 中国临床药理学与治疗学, 2021, 26(6): 662-671.
[4]	徐润泽, 韩静静, 李文倩, 杨劲. 从非临床到临床心律失常风险阶段评估体系研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 423-433.
[5]	张凌霄, 李婷, 许羚, 李禄金, 郑青山. 贝利木单抗治疗系统性红斑狼疮的模型化疗效评价[J]. 中国临床药理学与治疗学, 2021, 26(2): 174-181.
[6]	彭静, 刘俊, 许慧芳, 李越然, 江佳, 汪盛, 周德喜, 朱艳虹, 杨魁, 栾家杰. 细胞色素P4502C19基因多态性及代谢型与ADP诱导的血小板聚集抑制率及氯吡格雷抵抗的关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 746-751.
[7]	陈思雨陈露露王欣桐李晓晖余鹏欧阳冬生. 药用辅料对CYP3A活性的影响及其对仿制药质量和疗效一致性评价的指导作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 460-466.
[8]	吴茂锋, 刘畅, 戴慧晖, 麦长凤, 黄丹丽, 缪经纬, 刘丽忠, 方翼. pazopanib血药浓度个体差异与细胞色素P450 3A4基因多态性的关系初探[J]. 中国临床药理学与治疗学, 2020, 25(12): 1376-1380.
[9]	裴彤，郜丹，王春华，陈小平，龚诗立，胡晓，胡朝英，张兰. 吲达帕胺片的药动学和生物等效性研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1009-1014.
[10]	孔颖，李宁，卢杨，赵娣，任畅，邢晗，陈西敬. 肺吸入制剂的药代动力学评价手段研究进展[J]. 中国临床药理学与治疗学, 2019, 24(5): 595-600.
[11]	康辉，雍小兰，胡婷婷，储碧心，王蓝天. 国产拉科酰胺片的药动学及安全性评价[J]. 中国临床药理学与治疗学, 2019, 24(2): 192-197.
[12]	沈斌，蒋利亚，王晓凌，徐龙生，陆晓蕾，何家杨，孙佩玉，周月红，张小平. 中药注射剂超说明书用药研究与合理性评价[J]. 中国临床药理学与治疗学, 2019, 24(2): 223-227.
[13]	蔡妙国，邵卫，俞慧君，洪叶，施莉莉. SNI小鼠中调控ROS对疼痛和脊髓Pink1蛋白的影响及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(11): 1263-1268.
[14]	汪丽丽. 伏立康唑注射剂临床应用情况及合理性分析[J]. 中国临床药理学与治疗学, 2019, 24(1): 99-102.
[15]	韦柳萍，吴青，尹楠戈，杨彬，毛金校. 乳铁蛋白预防早产儿晚发型败血症有效性和安全性的系统评价[J]. 中国临床药理学与治疗学, 2018, 23(6): 653-660.